Evaluation Of Anti-Parkinson Activity of Eleocharis Dulchis in Albino Swiss Mice
The primary objectives of this research are to (1) isolate the active ingredients from Helicteres isora, (2) analyze their phytochemical composition, and (3) assess their potential as a treatment for mice with symptoms similar to Parkinson's disease. The Eleocharis dulchisplant was prepared for Soxhlet extraction by collecting its leaves and stems. Tannins identified by phytochemical screening included a wide variety of bioactive chemicals with possible medicinal uses, including carbs, proteins, saponins, flavonoids, alkaloids, phenols, fixed oils, lipids, and glycosides. The experimental setup involved inducing Parkinsonian-like symptoms in mice with haloperidol and then evaluating the therapeutic effects of Eleocharis dulcis extract (EOED) and Eleocharis dulchisextract using rotarod, actophotometer, and bar test measures of muscle tone and locomotor activity. Motor function improved throughout EOED treatment groups on the Rotarod test, with the highest dosage producing results similar to those of normal therapies. Locomotor activity was also shown to improve with increasing dosages of EOED in the Actophotometer test. Bromocriptine and high-dose EOED improved motor function, as seen by the varied levels of motor activity on the Bar Test. Researchers looked at oxidative stress indicators and dopamine levels as well. By combining bromocriptine with high-intensity electrical exercise (HIEE), UV spectroscopy was able to reverse the loss in dopamine levels caused by haloperidol. While HIEE demonstrated dose-dependent increases, bromocriptine's impact on dopamine was the most pronounced. Moreover, both HIEE and bromocriptine restored catalase (CAT) activity, which reduced brain oxidative stress; bromocriptine produced the greatest amounts of CAT. Combining Eleocharis dulchisextract with bromocriptine and HIEE may help alleviate symptoms similar to Parkinson's disease by restoring motor function and lowering oxidative stress, according to these results.
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2024-12-03
- DOI
- https://doi.org/10.5281/zenodo.14270362
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00